Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir
Drug Metabolism and Disposition · 2025
DOI: 10.1016/j.dmd.2025.100158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Abhinav Pentyala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, University of Colorado, Aurora…. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Carboxylesterase, Antiviral Agents, Alanine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
COVID-19 remains a significant health threat, particularly to people over the age of 65 with existing comorbidities like diabetes, hypertension, cancer, and viral infections. Despite expedited drug approvals, drug-drug interaction profiles for COVID-19 antiviral drugs have not yet been completely defined. The antiviral drugs remdesivir and molnupiravir are ester prodrugs with carboxylesterases (CES) playing a critical role in their bioactivation. In this study, we investigated the effect of COVID-19 antiviral drugs on CES hydrolysis activity. Of the 3 drugs tested, remdesivir inhibited 50% of CES2 activity in a nanomolar concentration range. Furthermore, time-dependent inhibition of CES2 activity by remdesivir was identified with an IC50 shift of nearly 3-fold from 0.188 μM after 5-minute preincubation to 0.068 μM following 40-minute preincubation. Remdesivir inactivation of CES2 was characterized by a kinact/KI value of 1.6 × 103 M-1.s-1. Through equilibrium dialysis and substrate protection experiments, we were able to further substantiate previous findings of the irreversible CES2 inhibition by remdesivir. Finally, in silico docking analysis of remdesivir to CES2 supported the proposed mechanism for covalent modification of the CES2 active site involving the catalytic triad serine via the phosphate group of remdesivir. SIGNIFICANCE STATEMENT: This study provides insights into human carboxylesterase inhibition by COVID-19 drugs and these findings demonstrate the underlying inhibition mechanism by remdesivir of recombinant human carboxylesterase 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address: jed.lampe@cuanschutz.edu.
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Pentyala, A., Kandel, S. E., & Lampe, J. N. (2025). Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100158
Vancouver
Pentyala A, Kandel SE, Lampe JN. Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100158
BibTeX
@article{Pentyala2025,
author = {Pentyala, Abhinav and Kandel, Sylvie E and Lampe, Jed N},
title = {Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir},
journal = {Drug Metabolism and Disposition},
year = {2025},
doi = {10.1016/j.dmd.2025.100158}
}
EUVIMED